Fig. 2. SETDB1 is a relatively unstable protein. (A) Cycloheximide (CHX), a protein synthesis inhibitor, was pretreated for 12 hr prior to doxorubicin or taxol treatment. Anticancer drug was treated for 12 hr. SETDB1 down-regulation was aggravated in the combination treatment, whereas other HMTases were not. (B) SETDB1 protein was decreased in the treatment of the RNA synthesis inhibitor, actinomycin D. Other HMTases were not changed in the same treatment.
